Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

Open access

Published version of a preprint

Abstract

The Cancer Genome Atlas project identified HER2 somatic mutations and gene amplification in 7% of patients with colorectal cancer. Introduction of the HER2 mutations S310F, L755S, V777L, V842I, and L866M into colon epithelial cells increased signaling pathways and anchorage-independent cell growth, indicating that they are activating mutations. Introduction of these HER2 activating mutations into colorectal cancer cell lines produced resistance to cetuximab and panitumumab by sustaining MAPK phosphorylation. HER2 mutants are potently inhibited by low nanomolar doses of the irreversible tyrosine kinase inhibitors neratinib and afatinib. HER2 gene sequencing of 48 cetuximab-resistant, quadruple (KRAS, NRAS, BRAF, and PIK3CA) wild-type (WT) colorectal cancer patient-derived xenografts (PDX) identified 4 PDXs with HER2 mutations. HER2-targeted therapies were tested on two PDXs. Treatment with a single HER2-targeted drug (trastuzumab, neratinib, or lapatinib) delayed tumor growth, but dual HER2-targeted therapy with trastuzumab plus tyrosine kinase inhibitors produced regression of these HER2-mutated PDXs. Significance: HER2 activating mutations cause EGFR antibody resistance in colorectal cell lines, and PDXs with HER2 mutations show durable tumor regression when treated with dual HER2-targeted therapy. These data provide a strong preclinical rationale for clinical trials targeting HER2 activating mutations in metastatic colorectal cancer. Cancer Discov; 5(8); 832–41. ©2015 AACR. See related commentary by Pectasides and Bass, p. 799. This article is highlighted in the In This Issue feature, p. 783

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-1211

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 302

Metadata

Authors
Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., Jacobs, S. A., Bertotti, A., & Bose, R.
Affiliations
  • Washington University in St. Louis (US)
  • Candiolo Cancer Institute (IT)
  • NSABP Foundation (US)
  • Istituto Nazionale Biostrutture e Biosistemi (IT)
Corresponding author
  • Bertotti, Andrea
  • Bose, Ron
Venue
Cancer Discovery
Published
2015-08-01
Volume
5
Issue
8
Pages
832-841
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2120921373
Cited by
302
References
39
Citations by year
2026: 18 · 2025: 16 · 2024: 22 · 2023: 34 · 2022: 30 · 2021: 30 · 2020: 28 · 2019: 36 · 2018: 37 · 2017: 24 · 2016: 20 · 2015: 7
FWCI
12.81
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
  • Memorial Sloan-Kettering Cancer Center
  • Ministero della Salute
  • Associazione Italiana per la Ricerca sul Cancro (14205, 15571)
  • National Institutes of Health
  • National Cancer Institute (R01CA161001)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
colorectal cancer, cetuximab resistance, MAPK signaling, tyrosine kinase inhibitors, neratinib, afatinib, trastuzumab, lapatinib, patient-derived xenografts, HER2 amplification
MeSH terms
Afatinib, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Cell Transformation, Neoplastic, Disease Models, Animal, Epithelial Cells, Humans, Mucous Membrane, Mutation, Quinazolines, Quinolines, Colorectal Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Molecular Targeted Therapy, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment. https://app.cochat.ai/papers/10.1158/2159-8290.cd-14-1211
The paper
Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., Jacobs, S. A., Bertotti, A., & Bose, R. (2015). HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-14-1211

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.